sorafenib

Also known as BAY 43-9006, Nexavar®, N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide, sorafenibum, Sorafenibum, N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea

Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.

Key facts

Drug.ChEMBL: 1336
Drug.PDB_ligand: BAX
Drug.verifiedrevid: 464405524
Drug.image: Sorafenib2DACS.svg
Drug.image_class: skin-invert-image
Drug.width: 300
Drug.image2: Sorafenib 3D 3gcs.png
Drug.image_class2: bg-transparent
Drug.width2: 250
Drug.tradename: Nexavar, others
Drug.MedlinePlus: a607051
Drug.DailyMedID: Sorafenib
Drug.licence_EU

~7 min read

Article

21 sections

Contents

Mechanism of action
Medical uses
Kidney cancer
Liver cancer
Thyroid cancer
Acute Myeloid Leukaemia
Adverse effects
History
Renal cancer
Liver cancer
Society and culture
Nexavar controversy
Research
Lung
Ovarian cancer
Brain (recurrent glioblastoma)
Desmoid tumor (aggressive fibromatosis)
See also
Notes
References
External links

==Mechanism of action== Sorafenib is a protein kinase inhibitor with activity against many protein kinases, including VEGFR, PDGFR and RAF kinases. Of the RAF kinases, sorafenib is more selective for c-Raf than B-RAF. (See BRAF (gene)#Sorafenib for details the drug's interaction with B-Raf.)